Vaccines work by educating the immune system about the tumor’s identity, but it can be challenging to deliver that “intel” to the proper cells that can act upon it. To address that, Dr. Lajoie is using nanoparticles to improve our ability to deliver that information successfully. His system is unique in that the nanoparticles are made from self-assembling proteins, which allows their structure to be encoded in DNA or RNA. This also makes it easy to make modifications and tailor the nanoparticle properties to ensure that their inner payload is delivered to the right place within the right cells. After validating the approach in cells, Dr. Lajoie will test the approach in mice. If successful, the hope is that it could then be used to improve survival in human patients.
University of Washington | All Cancers | 2016 | David A. Baker, Ph.D.
Marc J. Lajoie et al | Science | 2022 | DOI
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.